| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
CFO and Cbo
1 company
Sandeep Laumas is CFO and Cbo at TIL. Sandeep Laumas's net worth is not public. Form 4 filings only show shares in the companies where this person is an insider.
Sandeep Laumas has 21 Form 4 filings on record from March 2018 to May 2026, across 3 companies: Director at Unicycive Therapeutics (UNCY), 2023–2026; Director at BioXcel Therapeutics (BTAI), 2018–2026; CFO and Cbo at Instil Bio (TIL), 2021–2025.
The 26 reported transactions were 22 option or other derivative awards, 2 option exercises and 2 open-market sales.
Counted by filing, the open-market trades come to no purchases and 1 sale worth about $702K.
The only open-market sale was 30,000 shares of TIL at an average $23.39 on September 10, 2025, about $702K. Twelve months later TIL was down 68%.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | 3M | 12M | SEC |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 10, 2025 | TIL Instil Bio, Inc. | CFO and Cbo | Sale+OE | 30,000 | $23.39 | $701,667.24 | - | -52.0% | -68.0% |